Trial Profile
Randomized Phase II Trial of S-1 Versus S-1 plus Oxaliplatin (Sox) in Patients with Gemcitabine Refractory Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2017
Price :
$35
*
At a glance
- Drugs Oxaliplatin (Primary) ; Gimeracil/oteracil/tegafur
- Indications Adenosquamous carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Yakult Honsha
- 06 Jun 2017 Results of pooled analysis of three studies including this study presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 31 May 2013 According to a Yakult Honsha media release, the company has submitted supplemental new drug applications relating to an additional indication for pancreatic cancer, with respect to its products, Campto (40mg and 100mg), Elplat (50mg, 100mg and 200mg), and Levofolinate [Yakult] (25mg and 100mg), to the Japanese Ministry of Health, Labor and Welfare (MHLW).
- 30 Oct 2012 New trial record